Add Yahoo as a preferred source to see more of our stories on Google. Oct. 31—(StatePoint) November is Pulmonary Hypertension Awareness Month, and the American Lung Association, with support from ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection ...

Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced ...

Please provide your email address to receive an email when new articles are posted on . Engagement in daily pulmonary artery pressure readings may benefit patients with heart failure. Patients made ...

Pulmonary hypertension is traditionally defined as a mean pulmonary artery pressure of ≥25 mmHg when a patient is at rest, though a mean pressure of >20 mm Hg is considered to be abnormal and may ...

New findings reveal pulmonary arterial hypertension may affect the brain early. Learn how inflammation and cognitive decline ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted premarket approval to Endotronix’s pulmonary artery sensor platform for remote management of ...

Panelists discuss how managing patients with comorbidities requires careful evaluation to distinguish true Group 1 PAH features from underlying cardiac or pulmonary disease, with a more measured ...

In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this report, we follow up on what has happened since. After the FDA approved both ...